Kadmon Corporation

Delisted (Nasdaq: KDMN): acquired by Sanofi, completed 2021-11-09

Assets

(1 total)
1Total Assets
1Approved
0Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Approved
Rho-associated kinase (ROCK, pan)Small molecule
Graft-versus-Host Disease
Chronic Graft-versus-Host Disease

Upcoming events

(5 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
September 2027 (1)
BelumosudilPhase 1/2Plasma Cell Myeloma Refractory
Est. primary completion 2027-09-13 · NCT04643002 · CT.gov ↗
What to watch
2028 (2)
September 2028 (2)
BelumosudilPhase 2Chronic Graft Versus Host Disease
Est. primary completion 2028-09-25 · NCT07116031 · CT.gov ↗
What to watch
BelumosudilPhase 3Chronic Graft Versus Host Disease
Est. primary completion 2028-09-29 · NCT06143891 · CT.gov ↗
What to watch
2029 (2)
January 2029 (1)
BelumosudilPhase 3Lung Transplant Rejection
Est. primary completion 2029-01-29 · NCT06082037 · CT.gov ↗
What to watch
September 2029 (1)
BelumosudilPhase 3Chronic Graft Versus Host Disease
Est. primary completion 2029-09-14 · NCT07771439 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.